Boston Scientific (NYSE:BSX) Price Target Cut to $87.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its price target reduced by Citigroup from $94.00 to $87.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently issued reports on the stock. Evercore reduced their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. JPMorgan Chase & Co. reduced their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Morgan Stanley reduced their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.05.

Boston Scientific Price Performance

Shares of BSX stock opened at $61.83 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm’s 50-day moving average is $73.35 and its two-hundred day moving average is $88.76. Boston Scientific has a 12 month low of $60.90 and a 12 month high of $109.50. The company has a market capitalization of $91.89 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently added to or reduced their stakes in the business. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Steph & Co. purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Finally, Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” after the CHAMPION‑AF readout met primary safety and efficacy endpoints — a clinical win that supports Boston Scientific’s electrophysiology franchise and long‑term revenue potential. Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
• Positive Sentiment: Boston Scientific closed its acquisition of Valencia Technologies, strengthening its position against Medtronic in a currently under‑penetrated market — a strategic tuck‑in that could expand future addressable market and product offering. Boston Scientific closes buyout of Valencia Technologies
• Neutral Sentiment: Citigroup cut its price target from $94 to $87 but kept a “Buy” rating — this reduces near‑term upside from prior forecasts but maintains analyst conviction in BSX’s longer‑term thesis. Benzinga
• Negative Sentiment: Multiple securities‑fraud class action filings and numerous law‑firm shareholder alerts (Pomerantz, Gross, Bernstein Liebhard, Rosen, Levi & Korsinsky, Glancy Prongay Wolke, Faruqi & Faruqi, etc.) cite alleged disclosure issues covering July 23, 2025–Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline — increased litigation risk can pressure the stock via uncertainty and potential liability. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why Representative lawsuit coverage
• Negative Sentiment: Market commentary (e.g., Zacks) flagged today’s share decline relative to broader gains, suggesting selling pressure tied to the legal headlines and recent analyst adjustments. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.